BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28818847)

  • 1. A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.
    Caillard S; Cellot E; Dantal J; Thaunat O; Provot F; Janbon B; Buchler M; Anglicheau D; Merville P; Lang P; Frimat L; Colosio C; Alamartine E; Kamar N; Heng AE; Durrbach A; Moal V; Rivalan J; Etienne I; Peraldi MN; Moreau A; Moulin B;
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1663-1670. PubMed ID: 28818847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retransplantation after post transplant lymphoproliferative disorder: overcoming the obstacles!
    Prasad P; Khullar D; Gupta N; Grover R; Chhabra G; Gandhi KR; Gupta S; Bagai S
    CEN Case Rep; 2020 Aug; 9(3):200-203. PubMed ID: 32016786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA; Hamilton-Dutoit S; Bendtzen K
    Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful renal retransplantation after post-transplant lymphoproliferative disease.
    Karras A; Thervet E; Le Meur Y; Baudet-Bonneville V; Kessler M; Legendre C
    Am J Transplant; 2004 Nov; 4(11):1904-9. PubMed ID: 15476493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
    Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
    Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
    Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
    Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Post-transplantation lymphoproliferative disorder in childhood].
    Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
    Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
    Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
    Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor.
    Nieto-Rios JF; Gómez de Los Ríos SM; Serna-Higuita LM; Ocampo-Kohn C; Aristizabal-Alzate A; Gálvez-Cárdenas KM; Zuluaga-Valencia GA
    Colomb Med (Cali); 2016 Dec; 47(4):196-202. PubMed ID: 28293043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
    Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
    Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disorder after kidney transplantation: time to adopt monitoring of Epstein-Barr virus?
    Biller P; Michaux L; Pauw LD; Camboni A; Mourad M; Kanaan N
    Acta Clin Belg; 2015 Jun; 70(3):218-22. PubMed ID: 25541210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retransplantation after post-transplant lymphoproliferative disease.
    Demircin G; Rees L
    Pediatr Nephrol; 1997 Jun; 11(3):358-60. PubMed ID: 9203193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study.
    Maksten EF; Vase MØ; Kampmann J; d'Amore F; Møller MB; Strandhave C; Bendix K; Bistrup C; Thiesson HC; Søndergaard E; Hamilton-Dutoit S; Jespersen B
    Transpl Int; 2016 Apr; 29(4):483-93. PubMed ID: 26749337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.